Key Points
- Alfred Sandrock, Voyager's CEO, sold 12,192 shares on Feb. 10 at an average price of $3.78 for $46,085.76, trimming his stake by 2.33% to 509,989 shares (≈$1.93M) as disclosed in an SEC filing.
- Voyager's stock trades in the mid‑$3s (opened $3.65) with a market cap of about $203M and a 12‑month range of $2.64–$5.55; the company reported last quarter EPS of -$0.47 and revenue of $11.15M but remains deeply unprofitable (net margin -404.85%).
- Analysts hold a consensus "Moderate Buy" rating with an average price target of $13.75 (five Buys, one Sell), and institutional/hedge funds own roughly 48% of the company.
Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) insider Todd Alfred Carter sold 3,525 shares of the firm's stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $3.85, for a total transaction of $13,571.25. Following the transaction, the insider directly owned 153,193 shares in the company, valued at $589,793.05. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Voyager Therapeutics Stock Performance
Shares of NASDAQ:VYGR opened at $3.65 on Thursday. The company has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $4.09. Voyager Therapeutics, Inc. has a one year low of $2.64 and a one year high of $5.55. The stock has a market capitalization of $202.94 million, a price-to-earnings ratio of -1.69 and a beta of 1.30.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.06. The firm had revenue of $11.15 million for the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. As a group, research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Analyst Ratings Changes
VYGR has been the topic of several recent research reports. Wall Street Zen raised shares of Voyager Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Finally, HC Wainwright cut their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.75.
View Our Latest Report on VYGR
Institutional Trading of Voyager Therapeutics
Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in shares of Voyager Therapeutics in the second quarter valued at $36,000. Wexford Capital LP acquired a new stake in Voyager Therapeutics in the 3rd quarter valued at about $42,000. ProShare Advisors LLC purchased a new position in Voyager Therapeutics during the 4th quarter valued at about $44,000. CIBC Asset Management Inc acquired a new position in Voyager Therapeutics during the fourth quarter worth about $45,000. Finally, R Squared Ltd acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $48,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
